TScan is a clinical-stage biotechnology company dedicated to creating life-changing T-cell therapies for patients by unleashing the untapped potential of the human immune system

Dec 9, 2024 · TScan Therapeutics to Present Updated Data from the Ongoing ALLOHA™ Phase 1 Heme Trial During Oral Session at the 66th American Society of Hematology Annual Meeting and …

Mr. Nicholson has served as a member of our board of directors since June 2024. Mr. Nicholson has more than 35 years of pharmaceutical and biotech oncology experience. Mr. Nicholson currently …

The TSCAN-001 trial is studying TCR-Ts engineered to target MiHAs HA-1 (TSC-100) or HA-2 (TSC-101) to eliminate residual recipient blood cells post-HCT, thus preventing relapse

ReceptorScan enables identification of highly active T cell receptors, or TCRs, that recognize previously identified, clinically validated targets. Using ReceptorScan, we have identified our two lead TCR-T …

At TScan, we are focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies. TCRs are located on the surface of T cells and recognize antigens, ultimately triggering T …

TScan’s multiplexing approach has the potential to overcome target heterogeneity A 250 B

TScan has developed the engineered T cell products TSC-100 and TSC-101 that express TCRs targeting MiHAs HA-1 and HA-2 respectively, both presented by HLA-A*02:01 and expressed only in …

As TScan’s ImmunoBank grows, more customized T-Plex products can be built to overcome multiple intratumor heterogeneity scenarios with respect to cancer-associated proteins and/or HLA …

TScan is a clinical-stage biotechnology company dedicated to changing lives by developing safe and effective T-cell therapies for patients.